One drug's logic doesn't apply to another—toxicity differs, sequencing matters.
For decades, oncologists treating thyroid cancer navigated a rapidly expanding therapeutic landscape without a shared map. In April 2026, the American Society of Clinical Oncology offered one — its first comprehensive guideline on systemic therapy for thyroid malignancies — acknowledging that the proliferation of targeted agents and immunotherapies had outpaced the clinical wisdom needed to deploy them wisely. The guideline does not resolve every uncertainty, but it gives practitioners a principled framework for making consequential decisions in a field where waiting for perfect evidence is a luxury patients cannot afford.
- Oncologists treating five distinct thyroid cancer subtypes have long faced a critical void: no unified guidance on when to use lenvatinib, sorafenib, BRAF inhibitors, or PD-1/PD-L1 agents — or in what order.
- The stakes are sharpest for anaplastic thyroid cancer, once nearly uniformly fatal, where recent systemic advances are beginning to shift outcomes and rapid BRAFV600E testing is now central to the treatment decision.
- The evidence base is deeply uneven — 25 studies support anaplastic disease recommendations, but only three exist for high-grade and poorly differentiated subtypes, forcing the panel to extrapolate where data run thin.
- ASCO's expert panel, co-chaired by specialists from Emory and Stanford, synthesized 66 studies from a 25-year literature sweep to produce recommendations that distinguish strong evidence from weak — and name the difference honestly.
- The guideline lands not as a final answer but as a navigational waypoint, with future work needed on sequencing immunotherapy combinations, integrating novel agents into earlier-stage disease, and enrolling more rare-cancer patients in trials.
For years, oncologists treating thyroid cancer worked without a unified roadmap. Targeted drugs were arriving, immunotherapy options were expanding, and molecular testing was opening doors to precision treatment — but no comprehensive clinical guidance existed to help doctors decide which therapy to use, or when, across the disease's distinct subtypes. That gap closed in April when the American Society of Clinical Oncology released its first detailed guideline on systemic therapy for thyroid cancer.
The guideline was built by an expert panel co-chaired by Nabil Saba of Emory University and Beth Beadle of Stanford University, who faced a sprawling challenge: five thyroid cancer subtypes, each with its own biology, and a growing arsenal of agents — lenvatinib, sorafenib, BRAF-directed therapies, PD-1 and PD-L1 inhibitors — that don't all work the same way or fit the same clinical moment. The panel reviewed 1,146 articles published between 2000 and 2025, ultimately grounding their recommendations in 66 studies.
The evidence, however, was uneven. Anaplastic thyroid cancer had 25 studies behind it; medullary disease had 22; well-differentiated carcinoma had 16. But high-grade and poorly differentiated subtypes — rarer presentations that fall between these categories — had only three. For those cases, the panel had to extrapolate from subgroup analyses and lessons learned elsewhere, a limitation the guideline names openly.
The recommendations reflect how treatment thinking has shifted. For anaplastic thyroid cancer, the guideline now calls for rapid BRAFV600E mutation testing, with BRAF-directed systemic therapy for advanced disease. For recurrent or metastatic differentiated disease after surgery and radioactive iodine, lenvatinib, sorafenib, or immunotherapy inhibitors may be appropriate depending on individual factors. Beadle emphasized that the guideline's real power lies in helping clinicians distinguish between strong evidence, weak evidence, and no evidence at all — and then decide how to proceed when data are sparse.
Both co-chairs acknowledged the guideline is not an endpoint but a waypoint. Future updates will need to address how newer agents fit into earlier-stage disease, how to sequence multiple systemic therapies, and how immunotherapy combinations might reshape treatment. Equally pressing: enrolling more patients with rare thyroid cancers in clinical trials so that future guidance rests on firmer ground. For now, the guideline gives oncologists a framework for a field that has long outpaced its own clinical wisdom.
For years, oncologists treating thyroid cancer operated without a unified roadmap. The field was moving fast—new targeted drugs arriving, immunotherapy options expanding, molecular testing opening doors to precision treatment—but no comprehensive clinical guidance existed to help doctors navigate which therapy to use when, or how to sequence them across the different types of thyroid malignancy. That gap closed in April when the American Society of Clinical Oncology released its first detailed guideline on systemic therapy for thyroid cancer, a disease that turns out to be far more heterogeneous than its name suggests.
The guideline emerged from work by an expert panel co-chaired by Nabil Saba of Emory University and Beth Beadle of Stanford University. They faced a sprawling landscape: five distinct thyroid cancer subtypes, each with its own biology and treatment needs, and a growing arsenal of drugs—lenvatinib, sorafenib, PD-1 and PD-L1 inhibitors, BRAF-directed agents—that don't all work the same way or fit the same clinical moment. "Despite a rapidly evolving field of targeted and nontargeted systemic agents, no detailed guidance as to the use of these agents was previously available," Saba noted. The absence mattered. Thyroid cancer is rare enough that large randomized trials are often impractical, yet common enough that thousands of patients needed treatment decisions made in real time.
To build the guideline, the panel conducted a systematic literature review spanning 2000 to 2025, identifying 1,146 articles and ultimately including 66 studies in their analysis. The evidence, however, was uneven. Anaplastic thyroid cancer—the most aggressive form—had 25 studies behind it. Medullary disease had 22. Well-differentiated thyroid carcinoma, the most common type, had 16. But differentiated high-grade and poorly differentiated subtypes, which fall between these categories, had only three studies. For those rarer presentations, the panel had to extrapolate from subgroup analyses and lessons learned elsewhere, a reality that underscores both the guideline's value and its limitations.
The recommendations themselves reflect how treatment thinking has shifted. For anaplastic thyroid cancer, which carries a grim prognosis, the guideline now emphasizes rapid workup including BRAFV600E mutation testing, followed by neoadjuvant therapy in some cases and BRAF-directed systemic therapy for advanced disease. For patients with recurrent or metastatic differentiated high-grade or poorly differentiated thyroid carcinoma after surgery and radioactive iodine treatment, lenvatinib, sorafenib, or immunotherapy inhibitors may be appropriate depending on individual factors. The key insight is that one drug's logic doesn't necessarily apply to another. Toxicity profiles differ. Sequencing matters. The heterogeneity of the agents mirrors the heterogeneity of the disease itself.
Beadle emphasized that the guideline's real power lies in helping clinicians distinguish between strong evidence, weak evidence, and no evidence at all—and then decide how to proceed when data are sparse. "We wish to make recommendations based on the highest quality data, but we also want to use the lessons learned from all trials to try to inform the treatment of patients with rare cancers," she said. That pragmatism reflects clinical reality: oncologists cannot wait for perfect evidence when patients need treatment now.
Both co-chairs pointed to anaplastic thyroid cancer as an example of why the guideline arrived at the right moment. Recent systemic therapy advances have begun to improve outcomes in a disease that was once nearly uniformly fatal. That shift alone justifies the work of synthesizing and organizing what the field has learned. Yet they also acknowledged that the guideline is not an endpoint but a waypoint. Future updates will need to address how newer agents fit into earlier-stage disease, how to sequence multiple systemic therapies together, and how immunotherapy combinations might reshape treatment. Equally important: getting more patients with rare thyroid cancers into clinical trials so that future guidelines rest on firmer ground.
For now, the guideline gives oncologists a framework—a way to think through diagnosis, molecular testing, and treatment sequencing in a field that has outpaced its own guidance. It signals that thyroid cancer treatment has entered a new era, one where precision and multidisciplinary care matter more than ever, and where staying current is not optional.
Citas Notables
Despite a rapidly evolving field of targeted and nontargeted systemic agents, no detailed guidance as to the use of these agents was previously available for oncologists.— Nabil F. Saba, MD, Emory University, co-chair of the Expert Panel
The guideline is important because it identifies where we have strong data, where we have no or little data, and how to proceed when in a data-free or limited data zone.— Beth M. Beadle, MD, Stanford University, co-chair of the Expert Panel
La Conversación del Hearth Otra perspectiva de la historia
Why did ASCO need to issue this guideline now, after all these years of treating thyroid cancer?
The field exploded. New drugs arrived faster than guidance could be written. Doctors had lenvatinib, sorafenib, immunotherapy inhibitors—all effective in different ways—but no clear map for when to use which one. Thyroid cancer is rare enough that big trials are hard to run, so the evidence came in fragments.
You mentioned the evidence is uneven across cancer subtypes. What does that actually mean for a patient with the rarer types?
It means their treatment might be informed by studies done in other thyroid cancers, not their own. The panel had only three studies for high-grade and poorly differentiated types, so they borrowed lessons from anaplastic and well-differentiated disease. It's not guessing, but it's not the same as having a dedicated trial either.
What changed about how doctors treat anaplastic thyroid cancer specifically?
It's the biggest shift in the guideline. Anaplastic cancer used to be almost uniformly fatal. Now, if you catch the BRAFV600E mutation and treat it aggressively with targeted therapy, some patients are living longer. That improvement alone made this guideline urgent.
The guideline mentions molecular testing at the start. How much does that change the treatment path?
Completely. A BRAF mutation means one treatment strategy. No mutation means another. Without testing upfront, you're flying blind. The guideline makes clear that diagnosis, staging, and molecular work need to happen together, not sequentially.
What's still missing? What will the next version of this guideline need to address?
How to combine these drugs. Right now we know lenvatinib works, sorafenib works, immunotherapy works—but what happens when you use them together? And how do we get more rare cancer patients into trials so the evidence base isn't so thin? That's the frontier.